B-Cell Immune Checkpoints Come of Age in Cardio-oncology

HomeCirculation ResearchVol. 134, No. 5B-Cell Immune Checkpoints Come of Age in Cardio-oncology No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextB-Cell Immune Checkpoints Come of Age in Cardio-oncology Alan Gutierrez and Javid J. Moslehi Alan GutierrezAlan Gutierrez https://orcid.org/0000-0001-9129-243X Section of Cardio-Oncology and Immunology, Cardiovascular Research Institute (CVRI), University of California San Francisco, School of Medicine (A.G., J.M.). Yale University School of Medicine, New Haven, CT (A.G.). and Javid J. MoslehiJavid J. Moslehi Correspondance to: Javid J. Moslehi, MD, Section of Cardio-Oncology and Immunology, Cardiovascular Research Institute (CVRI), University of California San Francisco, School of Medicine, 555 Mission Bay Blvd. S., Room 452V San Francisco, CA 94143-3118. Email: E-mail Address: [email protected] https://orcid.org/0000-0001-5443-4312 Section of Cardio-Oncology and Immunology, Cardiovascular Research Institute (CVRI), University of California San Francisco, School of Medicine (A.G., J.M.). Originally published29 Feb 2024https://doi.org/10.1161/CIRCRESAHA.124.324243Circulation Research. 2024;134:569–571This article is a commentary on the followingExercise Inhibits Doxorubicin-Induced Cardiotoxicity via Regulating B CellsFootnotesFor Disclosures, see page 571.The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondance to: Javid J. Moslehi, MD, Section of Cardio-Oncology and Immunology, Cardiovascular Research Institute (CVRI), University of California San Francisco, School of Medicine, 555 Mission Bay Blvd. S., Room 452V San Francisco, CA 94143-3118. Email: Javid.moslehi@ucsf.eduREFERENCES1. Cohen CD, Rousseau ST, Bermea KC, Bhalodia A, Lovell JP, Zita MD, Cihakova D, Adamo L. Myocardial immune cells: the basis of cardiac immunology.J Immunol. 2023; 210:1198–1207. doi: 10.4049/jimmunol.2200924CrossrefMedlineGoogle Scholar2. Adamo L, Rocha-Resende C, Mann DL. The emerging role of B lymphocytes in cardiovascular disease.Annu Rev Immunol. 2020; 38:99–121. doi: 10.1146/annurev-immunol-042617-053104CrossrefMedlineGoogle Scholar3. Zouggari Y, Ait-Oufella H, Bonnin P, Simon T, Sage AP, Guerin C, Vilar J, Caligiuri G, Tsiantoulas D, Laurans L, et al. B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction.Nat Med. 2013; 19:1273–1280. doi: 10.1038/nm.3284CrossrefMedlineGoogle Scholar4. Wu L, Dalal R, Cao CD, Postoak JL, Yang G, Zhang Q, Wang Z, Lal H, Van Kaer L. IL-10-producing B cells are enriched in murine pericardial adipose tissues and ameliorate the outcome of acute myocardial infarction.Proc Natl Acad Sci U S A. 2019; 116:21673–21684. doi: 10.1073/pnas.1911464116CrossrefMedlineGoogle Scholar5. Asnani A, Moslehi JJ, Adhikari BB, Baik AH, Beyer AM, de Boer RA, Ghigo A, Grumbach IM, Jain S, Zhu H; American Heart Association Council on Basic Cardiovascular Sciences; Cardio-Oncology Science Subcommittee of Council on Genomic and Precision Medicine and Council on Clinical Cardiology; Council on Peripheral Vascular Disease; and Council on Arteriosclerosis, Thrombosis and Vascular Biology. Preclinical models of cancer therapy-associated cardiovascular toxicity: a scientific statement from the American Heart Association.Circ Res. 2021; 129:e21–e34. doi: 10.1161/RES.0000000000000473LinkGoogle Scholar6. Naaktgeboren WR, Binyam D, Stuiver MM, Aaronson NK, Teske AJ, van Harten WH, Groen WG, May AM. Efficacy of physical exercise to offset anthracycline-induced cardiotoxicity: a systematic review and meta-analysis of clinical and preclinical studies.J Am Heart Assoc. 2021; 10:e021580. doi: 10.1161/JAHA.121.021580LinkGoogle Scholar7. Bhagat A, Shrestha P, Jeyabal P, Peng Z, Watowich SS, Kleinerman ES. Doxorubicin-induced cardiotoxicity is mediated by neutrophils through release of neutrophil elastase.Front Oncol. 2022; 12:947604. doi: 10.3389/fonc.2022.947604CrossrefMedlineGoogle Scholar8. Luo W, Zou X, Wang Y, Dong Z, Weng X, Pei Z, Song S, Zhao Y, Wei Z, Gao R, et al. Critical Role of the cGAS-STING pathway in doxorubicin-induced cardiotoxicity.Circ Res. 2023; 132:e223–e242. doi: 10.1161/CIRCRESAHA.122.321587LinkGoogle Scholar9. Lei Y, VanPortfliet JJ, Chen YF, Bryant JD, Li Y, Fails D, Torres-Odio S, Ragan KB, Deng J, Mohan A, et al. Cooperative sensing of mitochondrial DNA by ZBP1 and cGAS promotes cardiotoxicity.Cell. 2023; 186:3013–3032.e22. doi: 10.1016/j.cell.2023.05.039CrossrefMedlineGoogle Scholar10. Bhagat A, Shrestha P, Kleinerman ES. The innate immune system in cardiovascular diseases and its role in doxorubicin-induced cardiotoxicity.Int J Mol Sci . 2022; 23:14649. doi: 10.3390/ijms232314649CrossrefMedlineGoogle Scholar11. Wang J, Liu S, Meng X, Zhao X, Wang T, Lei Z, Lehmann HI, Li G, Alcaide P, et al. Exercise inhibits Doxorubicin-induced Cardiotoxicity via regulating B cells.Circ Res. 2024;134:550–568. doi: 10.1161/CIRCRESAHA.123.323346LinkGoogle Scholar12. Barlev AN, Malkiel S, Kurata-Sato I, Dorjee AL, Suurmond J, Diamond B. FcgammaRIIB regulates autoantibody responses by limiting marginal zone B cell activation.J Clin Invest. 2022; 132:e157250. doi: 10.1172/JCI157250CrossrefMedlineGoogle Scholar13. Tao RH, Kobayashi M, Yang Y, Kleinerman ES. Exercise inhibits doxorubicin-induced damage to cardiac vessels and activation of Hippo/YAP-mediated apoptosis.Cancers (Basel). 2021; 13:2740. doi: 10.3390/cancers13112740CrossrefMedlineGoogle Scholar14. Gustafson MP, Wheatley-Guy CM, Rosenthal AC, Gastineau DA, Katsanis E, Johnson BD, Simpson RJ. Exercise and the immune system: taking steps to improve responses to cancer immunotherapy.J ImmunoTher Cancer. 2021; 9:e001872. doi: 10.1136/jitc-2020-001872CrossrefMedlineGoogle Scholar15. Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L, Kitsis RN. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.J Clin Invest. 2021; 131:e145186. doi: 10.1172/JCI145186CrossrefMedlineGoogle Scholar16. Bod L, Kye YC, Shi J, Torlai Triglia E, Schnell A, Fessler J, Ostrowski SM, Von-Franque MY, Kuchroo JR, Barilla RM, et al. B-cell-specific checkpoint molecules that regulate anti-tumour immunity.Nature. 2023; 619:348–356. doi: 10.1038/s41586-023-06231-0CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesExercise Inhibits Doxorubicin-Induced Cardiotoxicity via Regulating B CellsJing Wang, et al. Circulation Research. 2024;134:550-568 March 1, 2024Vol 134, Issue 5 Advertisement Article InformationMetrics © 2024 American Heart Association, Inc.https://doi.org/10.1161/CIRCRESAHA.124.324243PMID: 38422182 Originally publishedFebruary 29, 2024 KeywordsEditorialsB-cellscardiotoxicitycardio-oncologydoxorubicinexerciseimmunity, innatePDF download Advertisement